ZURA Projected Dividend Yield
Ord/Zura Bio Ltd ( NASDAQ : ZURA )Zura Bio is a clinical-stage biotechnology company focused on developing medicines for immune and inflammatory disorders. Co. is developing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R a inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is at the Phase 2 clinical development stage. 20 YEAR PERFORMANCE RESULTS |
ZURA Dividend History Detail ZURA Dividend News ZURA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |